Figure_4.tif (203.61 kB)
Administration of anti-mouse TNFR1 on the day of immunization ameliorated EAE.
figure
posted on 2014-02-28, 03:07 authored by Sarah K. Williams, Olaf Maier, Roman Fischer, Richard Fairless, Sonja Hochmeister, Aleksandar Stojic, Lara Pick, Doreen Haar, Sylvia Musiol, Maria K. Storch, Klaus Pfizenmaier, Ricarda DiemAnti-mouse TNFR1 was injected intra-peritoneally in C57BL/6 mice, on the day of disease induction, at a dosage of 100 µg (equivalent to 5 mg/kg). Mice were subsequently monitored on a daily basis until 21 days after the onset of clinical symptoms (EAE day 21). Antibody treatment resulted in a reduced EAE severity compared to mice receiving control IgG (A, B). Furthermore, mice injected with anti-TNFR1 also showed a significant delay in the onset of spinal cord symptoms in comparison to mice receiving control IgG (C). (A) Results from one representative experiment out of four shown (control IgG n = 4; anti TNFR1 n = 6), (B, C) results from four combined experiments (control IgG n = 16, anti-TNFR1 n = 19). * P<0.05, **P<0.01.
History
Usage metrics
Categories
Keywords
immunologyModel organismsAnimal modelsmouseneuroscienceNeurobiology of disease and regenerationClinical immunologyAutoimmune diseasesMultiple sclerosisClinical research designAnimal models of diseaseneurologyInfectious diseases of the nervous systemencephalomyelitisanti-mousetnfr1immunizationameliorated
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC